1200443-21-5
1200443-21-5
Chemical Structure
Targocil
- CAS No.: 1200443-21-5
- Formula:C21H22ClN5O4S
- Molecular Weight:475.95
IUPAC Name: 3-((4-chlorophenyl)sulfonyl)-N,N-diethyl-7,8-dimethoxy-[1,2,3]triazolo[1,5-a]quinazolin-5-amine
InChIKey: TYNZGYMGTTUYKZ-UHFFFAOYSA-N
SMILES: COC1=CC2=C(C=C1OC)C(N(CC)CC)=NC3=C(S(=O)(C4=CC=C(Cl)C=C4)=O)N=NN32
Biological Activity: Targocil functions as a bacteriostatic inhibitor of wall teichoic acid (WTA) biosynthesis which can inhibit the growth of methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) with MIC90s of 2 μg/ mL for both MRSA and MSSA.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Targocil | 99.32% | Targocil functions as a bacteriostatic inhibitor of wall teichoic acid (WTA) biosynthesis which can inhibit the growth of methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) with MIC90s of 2 μg/ mL for both MRSA and MSSA. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MPT0B392 (Standard) | ≥98% | MPT0B392 (Standard) is the analytical standard of MPT0B392 (HY-101287). This product is intended for research and analytical applications. MPT0B392, an orally active quinoline derivative, induces c-Jun N-terminal kinase (JNK) activation, leading to apoptosis. MPT0B392 inhibits tubulin polymerization and triggers induction of the mitotic arrest, followed by mitochondrial membrane potential loss and caspases cleavage by activation of JNK and ultimately leads to apoptosis. MPT0B392 is demonstrated to be a novel microtubule-depolymerizing agent and enhances the cytotoxicity of sirolimus in sirolimus-resistant acute leukemic cells and the multidrug resistant cell line. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
UTA1inh-D1 | UTA1inh-D1 is a selective UT-A1 and UT-B urea transporter inhibitor with IC50 values of 3.8 μM and 15 μM, respectively. UTA1inh-D1 is promising for research of refractory edema, such as congestive heart failure and cirrhosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GSK-114 | 99.52% | GSK-114 is a highly selective, orally active TNNI3K inhibitor (IC50= 25 nM). GSK-114 shows a 40-fold selectivity for TNNI3K over B-Raf kinase (IC50= 1 μM). Cardiac troponin I-interacting kinase (TNNI3K or CARK) is a member of the tyrosine-like kinase family that is selectively expressed in heart tissue. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SR33805 analog | SR 33805 (analog) is an orally active Ca2+ channel blocker that selectively inhibits the proliferation of smooth muscle cells. SR 33805 (analog) reduces calcium uptake by blocking calcium channels, thereby inhibiting smooth muscle cell proliferation induced by serum, platelet-derived growth factor, and basic fibroblast growth factor. SR 33805 (analog) significantly reduces intimal thickening following endothelial injury in rabbits. SR 33805 (analog) shows promise for cardiovascular disease research, such as in early atherosclerosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
UT-B-IN-1 | 98.07% | UT-B-IN-1 (UTBINH-14) is a reversible, competitive and selective urea transporter-B (UT-B) inhibitor with IC50 values of 10 and 25 nM for human and mouse UT-B, respectively. UT-B-IN-1 shows low toxicity and high selectivity for UT-B over UT-A isoforms. UT-B-IN-1 increases urine output and reduces urine osmolality of mice. UT-B-IN-1 can be used for diuretic mechanism research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SR33805 | 99.78% | SR33805 is a potent Ca2+ channel antagonist, with EC50s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 blocks L-type but not T-type Ca2+ channels. SR33805 can be used for the research of acute or chronic failing hearts. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Enpp-1-IN-6 | Enpp-1-IN-6 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-6 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Enpp-1-IN-8 | Enpp-1-IN-8 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-8 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PXR Ligand 3 | PXR Ligand 3 is a PXP ligand. PXR Ligand 3 can be used to synthesize PROTAC MI1013 (HY-175266). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Savirin | Savirin exhibits in vitro antibacterial and antibiofilm activity. Savirin can prevent skin infections induced by S. aureus in vivo. Savirin shows enhanced activity when combined with antibiotics. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
